Inclusion Criteria:

1. Man or woman aged 18 to 65 years old;

2. Subjects are newly diagnosed MM patients which are scheduled by the investigators to
be treated with vincristine, adriamycin and dexamethasone standard therapy. Stage
II/III (according to Durie and Salmon criteria) with skeletal involvement, such as
bone pain, bone lytic lesions, diffuse osteoporosis or pathologic fractures;

3. Life expectancy > 3 months;

4. Patient has measurable disease in which to capture response, defined as one or more
of the following;

- Serum M-protein level >10.0 g/L measured by serum protein electrophoresis or
immunoglobulin electrophoresis; or

- Urinary M-protein excretion > 1 g/24 hours; or

- Bone marrow plasmacytosis of > 30% by bone marrow aspirate and/or biopsy; or

- Serum free light chains (by the Freelite test) > 2 X the upper limit of normal
(ULN), in the absence of renal failure.

5. Performance status (PS) of ECOG ≤2.0, unless PS of 3-4 based solely on bone pain;

6. Patients must have a Platelets count≥50×109 cells /L; Absolute neutrophil count
(ANC)≥0.75×109 cells /L;

7. Patients must have adequate hepatic function defined as Alanine transaminase(ALT) ≤
2.5 × upper limit of normal(ULN); Aspartate transaminase (AST) ≤2.5×ULN; Total
bilirubin ≤2×ULN;

8. Patients must have adequate renal function defined as creatinine clearance >30 ml
/min;

9. Subjects (or their legally acceptable representatives) must have signed a informed
consent document indicating that they understand the purpose of and procedures
required for the study and are willing to participate in the study.

Exclusion Criteria:

1. Non-secretory MM, unless the patient has measurable lesions on computed tomography
(CT), magnetic resonance imaging (MRI) and/or positron emission tomography (PET);

2. Peripheral neuropathy or neuropathy pain grade 2 or high as defined by National
Cancer Institute Common Terminology Criteria for Adverse Events(NCI CTCAE) Version 3;

3. Uncontrolled or severe cardiovascular disease, including myocardial infarction (MI )
within 6 months of enrollment, New York Heart Association (NYHA) Class III or IV
heart failure, uncontrolled angina, clinically significant pericardial disease, or
cardiac amyloidosis;

4. History of allergy reaction attributable to compounds containing boron or mannitol;

5. Any serious, active disease or psychiatric illness that could potentially interfere
with the completion of treatment according to this protocol or the investigator's
decision;

6. Concurrent treatment with another investigational agent;

7. Female subject who is pregnant or breast-feeding.